DrugPatentWatch Database Preview
Horizon Company Profile
What is the competitive landscape for HORIZON, and what generic alternatives to HORIZON drugs are available?
HORIZON has seven approved drugs.
There are forty-seven US patents protecting HORIZON drugs.
There are three hundred and thirteen patent family members on HORIZON drugs in fifty-three countries and seventy-three supplementary protection certificates in fifteen countries.
Summary for Horizon
| International Patents: | 313 |
| US Patents: | 47 |
| Tradenames: | 6 |
| Ingredients: | 6 |
| NDAs: | 7 |
| Patent Litigation for Horizon: | See patent lawsuits for Horizon |
| PTAB Cases with Horizon as patent owner: | See PTAB cases with Horizon as patent owner |
Drugs and US Patents for Horizon
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Horizon Theraps Inc | RAVICTI | glycerol phenylbutyrate | LIQUID;ORAL | 203284-001 | Feb 1, 2013 | RX | Yes | Yes | 9,095,559 | ➤ Sign Up | ➤ Sign Up | ||||
| Horizon Pharma Usa | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-001 | Apr 30, 2013 | RX | Yes | No | 9,925,156 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Horizon Theraps Inc | RAVICTI | glycerol phenylbutyrate | LIQUID;ORAL | 203284-001 | Feb 1, 2013 | RX | Yes | Yes | 9,254,278 | ➤ Sign Up | ➤ Sign Up | ||||
| Horizon Pharma | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-001 | Jul 26, 2012 | AB | RX | Yes | No | 6,488,960 | ➤ Sign Up | Y | ➤ Sign Up | ||
| Horizon Pharma | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-002 | Jul 26, 2012 | AB | RX | Yes | No | 9,504,699 | ➤ Sign Up | ➤ Sign Up | |||
| Horizon Theraps Inc | RAVICTI | glycerol phenylbutyrate | LIQUID;ORAL | 203284-001 | Feb 1, 2013 | RX | Yes | Yes | 8,404,215 | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Horizon
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | 5,714,504*PED | ➤ Sign Up |
| Horizon Theraps Inc | RAVICTI | glycerol phenylbutyrate | LIQUID;ORAL | 203284-001 | Feb 1, 2013 | 5,968,979 | ➤ Sign Up |
| Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | 6,875,872*PED | ➤ Sign Up |
| Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-001 | Apr 30, 2010 | 5,714,504*PED | ➤ Sign Up |
| Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-001 | Apr 30, 2010 | 6,875,872*PED | ➤ Sign Up |
| Horizon Pharma Inc | BUPHENYL | sodium phenylbutyrate | TABLET;ORAL | 020572-001 | May 13, 1996 | 4,457,942 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for HORIZON drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 800 mg/26.6 mg | ➤ Subscribe | 2011-12-06 |
| ➤ Subscribe | Oral Liquid | 1.1 g/mL | ➤ Subscribe | 2013-11-19 |
| ➤ Subscribe | Delayed-release Tablet | 375 mg/20 mg and 500 mg/20 mg | ➤ Subscribe | 2010-11-05 |
| ➤ Subscribe | Delayed-release Tablets | 1 mg, 2 mg, and 5 mg | ➤ Subscribe | 2012-11-26 |
International Patents for Horizon Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| South Korea | 20050042827 | ➤ Sign Up |
| United Kingdom | 0915545 | ➤ Sign Up |
| South Korea | 101430089 | ➤ Sign Up |
| Japan | 2012531409 | ➤ Sign Up |
| South Africa | 200809858 | ➤ Sign Up |
| Germany | 69829511 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Horizon Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 0854 | Netherlands | ➤ Sign Up | PRODUCT NAME: GLYCEROLFENYLBUTYRAAT; REGISTRATION NO/DATE: EU/1/15/1062 20151201 |
| 4 50001-2014 | Slovakia | ➤ Sign Up | PRODUCT NAME: MERKAPTAMIN; FIRST REGISTRATION: EU/1/13/861, 20130906 |
| 90018-6 | Sweden | ➤ Sign Up | PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119 |
| 2014000023 | Germany | ➤ Sign Up | PRODUCT NAME: CYSTEAMIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/13/861 20130906 |
| 90006-4 | Sweden | ➤ Sign Up | PRODUCT NAME: ACETYLSALICYLSYRA OCH ESOMEPRAZOLMAGNESIUMTRIHYDRAT; NAT. REG. NO/DATE: MTNR 44371 20110930; FIRST REG.: PT 5402359MFL 20110812 |
| 00481 | Netherlands | ➤ Sign Up | PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17901/0263-001 20101105 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
